Project Name：Lapatinib 

Registration Classification：3+6

Formulations and specifications ：Tablets: 0.25g 

Indications：Mainly for joint capecitabine ErbB-2 whose tumors overexpress HER2  , including previously treated with anthracycline , paclitaxel, trastuzumab ( Herceptin ) treatment of advanced or metastatic breast cancer.

Original Research Company：GlaxoSmithKline 

Progress ：Pharmaceutical Research in progress